A. D. Beadell Investment Counsel Inc. lessened its stake in Pfizer Inc. (NYSE:PFE – Get Rating) by 12.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,338 shares of the biopharmaceutical company's stock after selling 750 shares during the quarter. A. D. Beadell Investment Counsel Inc.'s holdings in Pfizer were worth $279,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds also recently bought and sold shares of the company. LMR Partners LLP bought a new stake in Pfizer during the 4th quarter valued at about $8,026,000. Continuum Advisory LLC increased its stake in Pfizer by 4.0% during the 4th quarter. Continuum Advisory LLC now owns 40,651 shares of the biopharmaceutical company's stock valued at $833,000 after purchasing an additional 1,561 shares in the last quarter. Baltimore Washington Financial Advisors Inc. bought a new stake in Pfizer during the 4th quarter valued at about $290,000. Red Door Wealth Management LLC increased its stake in Pfizer by 3.6% during the 4th quarter. Red Door Wealth Management LLC now owns 100,926 shares of the biopharmaceutical company's stock valued at $5,959,000 after purchasing an additional 3,552 shares in the last quarter. Finally, Stonebridge Capital Advisors LLC increased its stake in Pfizer by 5.4% during the 4th quarter. Stonebridge Capital Advisors LLC now owns 24,968 shares of the biopharmaceutical company's stock valued at $1,474,000 after purchasing an additional 1,290 shares in the last quarter. Institutional investors own 67.90% of the company's stock.
Get Pfizer alerts:Pfizer Price Performance
Shares of NYSE:PFE opened at $44.08 on Friday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.42 and a quick ratio of 1.20. Pfizer Inc. has a 1-year low of $40.94 and a 1-year high of $61.71. The company has a market capitalization of $247.39 billion, a P/E ratio of 8.63, a P/E/G ratio of 0.54 and a beta of 0.70. The firm's 50 day simple moving average is $48.24 and its two-hundred day simple moving average is $50.32.
Pfizer (NYSE:PFE – Get Rating) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.95 by $0.09. Pfizer had a net margin of 28.92% and a return on equity of 43.18%. The business had revenue of $27.74 billion for the quarter, compared to the consensus estimate of $26.20 billion. During the same quarter in the previous year, the firm earned $1.07 earnings per share. The company's revenue for the quarter was up 46.8% on a year-over-year basis. Research analysts expect that Pfizer Inc. will post 6.54 EPS for the current fiscal year.Pfizer Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Monday, December 5th. Shareholders of record on Friday, November 4th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 3.63%. The ex-dividend date of this dividend is Thursday, November 3rd. Pfizer's dividend payout ratio is currently 31.31%.
Analyst Ratings Changes
A number of analysts have recently commented on PFE shares. Barclays set a $50.00 price target on shares of Pfizer in a research note on Thursday, September 1st. Morgan Stanley reduced their price target on shares of Pfizer from $52.00 to $49.00 and set an "equal weight" rating for the company in a research note on Friday, July 8th. Berenberg Bank set a $44.00 price target on shares of Pfizer in a research note on Wednesday, September 14th. The Goldman Sachs Group set a $50.00 price target on shares of Pfizer in a research note on Thursday, September 1st. Finally, UBS Group set a $59.00 price target on shares of Pfizer in a research note on Thursday, September 1st. Nine research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $57.00.
About Pfizer
(Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
Featured Articles
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.